Targeting Ubiquitination for Cancer Therapies

References

• Hershko A , CiechanoverA. The ubiquitin system. Annu. Rev. Biochem.67425–479 (1998).
   PubMed Web of Science ®Google Scholar
• Hershko A . Ubiquitin: roles in protein modification and breakdown. Cell34 (1), 11–12 (1983).
   PubMed Web of Science ®Google Scholar
• Handley PM , MuecklerM, SiegelNR, CiechanoverA, SchwartzAL. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc. Natl Acad. Sci. USA88 (1), 258–262 (1991).
   PubMed Web of Science ®Google Scholar
• Schulman BA , HarperJW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol.10 (5), 319–331 (2009).
   PubMed Web of Science ®Google Scholar
• Jentsch S . The ubiquitin-conjugation system. Annu. Rev. Genet.26179–207 (1992).
   PubMed Web of Science ®Google Scholar
• Berndsen CE , WolbergerC. New insights into ubiquitin E3 ligase mechanism. Nat. Struct. Mol. Biol.21 (4), 301–307 (2014).
   PubMed Web of Science ®Google Scholar
• Nakayama KI , NakayamaK. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer6 (5), 369–381 (2006).
   PubMed Web of Science ®Google Scholar
• Hershko A , CiechanoverA. The ubiquitin system for protein degradation. Annu. Rev. Biochem.61, 761–807 (1992).
   PubMed Web of Science ®Google Scholar
• Ciechanover A . The ubiquitin-proteasome proteolytic pathway. Cell79 (1), 13–21 (1994).
   PubMed Web of Science ®Google Scholar
• Rieser E , CordierSM, WalczakH. Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem. Sci.38 (2), 94–102 (2013).
   PubMed Web of Science ®Google Scholar
• Komander D , RapeM. The ubiquitin code. Annu. Rev. Biochem.81, 203–229 (2012).
   PubMed Web of Science ®Google Scholar
• Chen ZJ , SunLJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell33 (3), 275–286 (2009).
   PubMed Web of Science ®Google Scholar
• Yang WL , ZhangX, LinHK. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene29 (32), 4493–4503 (2010).
   PubMed Web of Science ®Google Scholar
• Bach I , OstendorffHP. Orchestrating nuclear functions: ubiquitin sets the rhythm. Trends Biochem. Sci.28 (4), 189–195 (2003).
   PubMed Web of Science ®Google Scholar
• Murray AW . Recycling the cell cycle: cyclins revisited. Cell116 (2), 221–234 (2004).
   PubMed Web of Science ®Google Scholar
• Glotzer M , MurrayAW, KirschnerMW. Cyclin is degraded by the ubiquitin pathway. Nature349 (6305), 132–138 (1991).
   PubMed Web of Science ®Google Scholar
• Hoeller D , DikicI. Targeting the ubiquitin system in cancer therapy. Nature458 (7237), 438–444 (2009).
   PubMed Web of Science ®Google Scholar
• Lipkowitz S , WeissmanAM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer11 (9), 629–643 (2011).
   PubMed Web of Science ®Google Scholar
• Kirkin V , DikicI. Ubiquitin networks in cancer. Curr. Opin. Genet. Dev.21 (1), 21–28 (2011).
   PubMed Web of Science ®Google Scholar
• Pal A , YoungMA, DonatoNJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res.74 (18), 4955–4966 (2014).
   PubMed Web of Science ®Google Scholar
• Miranda M , SorkinA. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol. Interv.7 (3), 157–167 (2007).
   PubMedGoogle Scholar
• Hicke L , SchubertHL, HillCP. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol.6 (8), 610–621 (2005).
   PubMed Web of Science ®Google Scholar
• Pickart CM . Ubiquitin enters the new millennium. Mol. Cell8 (3), 499–504 (2001).
   PubMed Web of Science ®Google Scholar
• Sigismund S , PoloS, Di FiorePP. Signaling through monoubiquitination. Curr. Top. Microbiol. Immunol.286149–185 (2004).
   PubMed Web of Science ®Google Scholar
• Hicke L . Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol.2 (3), 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Adams J , KauffmanM. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest.22 (2), 304–311 (2004).
   PubMed Web of Science ®Google Scholar
• Dick LR , FlemingPE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today15 (5–6), 243–249 (2010).
   PubMed Web of Science ®Google Scholar
• Potts BC , AlbitarMX, AndersonKCet al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr. Cancer Drug Targets11 (3), 254–284 (2011).
   PubMed Web of Science ®Google Scholar
• Kumar SK , BerdejaJG, NiesvizkyRet al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label Phase 1/2 study. Lancet Oncol.15 (13), 1503–1512 (2014).
   PubMed Web of Science ®Google Scholar
• Micel LN , TentlerJJ, SmithPG, EckhardtGS. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J. Clin. Oncol.31 (9), 1231–1238 (2013).
   PubMed Web of Science ®Google Scholar
• Da Silva SR , PaivaSL, LukkarilaJL, GunningPT. Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes. J. Med. Chem.56 (6), 2165–2177 (2013).
   PubMed Web of Science ®Google Scholar
• Popovic D , VucicD, DikicI. Ubiquitination in disease pathogenesis and treatment. Nat. Med.20 (11), 1242–1253 (2014).
   PubMed Web of Science ®Google Scholar
• Nawrocki ST , GriffinP, KellyKR, CarewJS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin. Investig. Drugs21 (10), 1563–1573 (2012).
   PubMed Web of Science ®Google Scholar
• Swords RT , KellyKR, SmithPGet al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood115 (18), 3796–3800 (2010).
   PubMed Web of Science ®Google Scholar
• Deshaies RJ . Proteotoxic crisis, the ubiquitin–proteasome system, and cancer therapy. BMC Biol.1294 (2014).
   PubMed Web of Science ®Google Scholar
• Morrow JK , ZhangS. Computational prediction of protein hot spot residues. Curr. Pharm. Des.18 (9), 1255–1265 (2012).
   PubMed Web of Science ®Google Scholar
• Frankland-Searby S , BhaumikSR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta1825 (1), 64–76 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar SK , RajkumarSV, DispenzieriAet al. Improved survival in multiple myeloma and the impact of novel therapies. Blood111 (5), 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Bonvini P , ZorziE, BassoG, RosolenA. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia21 (4), 838–842 (2007).
   PubMed Web of Science ®Google Scholar
• Groll M , BerkersCR, PloeghHL, OvaaH. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure14 (3), 451–456 (2006).
   PubMed Web of Science ®Google Scholar
• Hideshima T , RichardsonPG, AndersonKC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther.10 (11), 2034–2042 (2011).
   PubMed Web of Science ®Google Scholar
• Gelman JS , SironiJ, BerezniukIet al. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS ONE8 (1), e53263 (2013).
   PubMed Web of Science ®Google Scholar
• Mattern MR , WuJ, NicholsonB. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim. Biophys. Acta1823 (11), 2014–2021 (2012).
   PubMed Web of Science ®Google Scholar
• Kubiczkova L , PourL, SedlarikovaL, HajekR, SevcikovaS. Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. J. Cell. Mol. Med.18 (6), 947–961 (2014).
   PubMed Web of Science ®Google Scholar
• Richardson PG , BriembergH, JagannathSet al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol.24 (19), 3113–3120 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson PG , BarlogieB, BerensonJet al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348 (26), 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki E , DemoS, DeuEet al. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS ONE6 (12), e27996 (2011).
   PubMed Web of Science ®Google Scholar
• Vij R , SiegelDS, JagannathSet al. An open-label, single-arm, Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol.158 (6), 739–748 (2012).
   PubMed Web of Science ®Google Scholar
• Vij R , WangM, KaufmanJLet al. An open-label, single-arm, Phase 2 (PX-171–004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood119 (24), 5661–5670 (2012).
   PubMed Web of Science ®Google Scholar
• Meng L , MohanR, KwokBH, ElofssonM, SinN, CrewsCM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl Acad. Sci. USA96 (18), 10403–10408 (1999).
   PubMed Web of Science ®Google Scholar
• Piva R , RuggeriB, WilliamsMet al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood111 (5), 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Tsukamoto S , TakeuchiT, RotinsuluHet al. Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorg. Med. Chem. Lett.18 (24), 6319–6320 (2008).
   PubMed Web of Science ®Google Scholar
• Dalisay DS , TsukamotoS, MolinskiTF. Absolute configuration of the alpha,omega-bifunctionalized sphingolipid leucettamol A from Leucetta microrhaphis by deconvoluted exciton coupled CD. J. Nat. Prod.72 (3), 353–359 (2009).
   PubMed Web of Science ®Google Scholar
• Ceccarelli DF , TangX, PelletierBet al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell145 (7), 1075–1087 (2011).
   PubMed Web of Science ®Google Scholar
• Ito T , AndoH, SuzukiTet al. Identification of a primary target of thalidomide teratogenicity. Science327 (5971), 1345–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Kim Y , Schmidt-WolfIG. Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther.15 (5), 491–497 (2015).
   PubMed Web of Science ®Google Scholar
• Lacy MQ , RajkumarSV. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. Am. J. Hematol.85 (2), 95–96 (2010).
   PubMed Web of Science ®Google Scholar
• Vassilev LT , VuBT, GravesBet al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science303 (5659), 844–848 (2004).
   PubMed Web of Science ®Google Scholar
• Vassilev LT . MDM2 inhibitors for cancer therapy. Trends Mol. Med.13 (1), 23–31 (2007).
   PubMed Web of Science ®Google Scholar
• Vu B , WovkulichP, PizzolatoGet al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett.4 (5), 466–469 (2013).
   PubMed Web of Science ®Google Scholar
• Gembarska A , LucianiF, FedeleCet al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med.18 (8), 1239–1247 (2012).
   PubMed Web of Science ®Google Scholar
• Chang YS , GravesB, GuerlavaisVet al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA110 (36), E3445–E3454 (2013).
   PubMed Web of Science ®Google Scholar
• Wang H , MaX, RenS, BuolamwiniJK, YanC. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther.10 (1), 69–79 (2011).
   PubMed Web of Science ®Google Scholar
• Ungermannova D , LeeJ, ZhangG, DallmannHG, MchenryCS, LiuX. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J. Biomol. Screen.18 (8), 910–920 (2013).
   PubMed Web of Science ®Google Scholar
• Orlicky S , TangX, NeduvaVet al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol.28 (7), 733–737 (2010).
   PubMed Web of Science ®Google Scholar
• Wu L , GrigoryanAV, LiY, HaoB, PaganoM, CardozoTJ. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem. Biol.19 (12), 1515–1524 (2012).
   PubMedGoogle Scholar
• Chen Q , XieW, KuhnDJet al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood111 (9), 4690–4699 (2008).
   PubMed Web of Science ®Google Scholar
• Chan CH , MorrowJK, LiCFet al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell154 (3), 556–568 (2013).
   PubMed Web of Science ®Google Scholar
• Nakajima H , FujiwaraH, FuruichiY, TanakaK, ShimbaraN. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem. Biophys. Res. Commun.368 (4), 1007–1013 (2008).
   PubMed Web of Science ®Google Scholar
• Blees JS , BokeschHR, RubsamenDet al. Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase beta-TrCP1. PLoS ONE7 (10), e46567 (2012).
   PubMed Web of Science ®Google Scholar
• Khoury K , DomlingA. P53 mdm2 inhibitors. Curr. Pharm. Des.18 (30), 4668–4678 (2012).
   PubMed Web of Science ®Google Scholar
• Tabernero J , DirixL, SchoffskiPet al. A Phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res.17 (19), 6313–6321 (2011).
   PubMed Web of Science ®Google Scholar
• Kapuria V , PetersonLF, FangD, BornmannWG, TalpazM, DonatoNJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res.70 (22), 9265–9276 (2010).
   PubMed Web of Science ®Google Scholar
• Lee BH , LeeMJ, ParkSet al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature467 (7312), 179–184 (2010).
   PubMed Web of Science ®Google Scholar
• Aleo E , HendersonCJ, FontaniniA, SolazzoB, BrancoliniC. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res.66 (18), 9235–9244 (2006).
   PubMed Web of Science ®Google Scholar
• Altun M , KramerHB, WillemsLIet al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol.18 (11), 1401–1412 (2011).
   PubMedGoogle Scholar
• Chauhan D , CatleyL, LiGet al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell8 (5), 407–419 (2005).
   PubMed Web of Science ®Google Scholar
• Millward M , PriceT, TownsendAet al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs30 (6), 2303–2317 (2012).
   PubMed Web of Science ®Google Scholar
• Kupperman E , LeeEC, CaoYet al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res.70 (5), 1970–1980 (2010).
   PubMed Web of Science ®Google Scholar
• Ushiyama S , UmaokaH, KatoHet al. Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13–Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa. J. Nat. Prod.75 (8), 1495–1499 (2012).
   PubMed Web of Science ®Google Scholar
• Metzger MB , HristovaVA, WeissmanAM. HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci.125 (3), 531–537 (2012).
   PubMed Web of Science ®Google Scholar
• Nijman SM , Luna-VargasMP, VeldsAet al. A genomic and functional inventory of deubiquitinating enzymes. Cell123 (5), 773–786 (2005).
   PubMed Web of Science ®Google Scholar
• Skaar JR , PaganJK, PaganoM. Mechanisms and function of substrate recruitment by F-box proteins. Nat. Rev. Mol. Cell Biol.14 (6), 369–381 (2013).
   PubMed Web of Science ®Google Scholar
• Lu G , MiddletonRE, SunHet al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science343 (6168), 305–309 (2014).
   PubMed Web of Science ®Google Scholar
• Fischer ES , BohmK, LydeardJRet al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature512 (7512), 49–53 (2014).
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A , MendyD, ItoTet al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia26 (11), 2326–2335 (2012).
   PubMed Web of Science ®Google Scholar
• Zhu YX , BraggioE, ShiCXet al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood118 (18), 4771–4779 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JT , GuW. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ.17 (1), 86–92 (2010).
   PubMed Web of Science ®Google Scholar
• Haupt Y , MayaR, KazazA, OrenM. Mdm2 promotes the rapid degradation of p53. Nature387 (6630), 296–299 (1997).
   PubMed Web of Science ®Google Scholar
• Honda R , TanakaH, YasudaH. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett.420 (1), 25–27 (1997).
   PubMed Web of Science ®Google Scholar
• Fang S , JensenJP, LudwigRL, VousdenKH, WeissmanAM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem.275 (12), 8945–8951 (2000).
   PubMed Web of Science ®Google Scholar
• Chargari C , LeteurC, AngevinEet al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett.312 (2), 209–218 (2011).
   PubMed Web of Science ®Google Scholar
• Van Maerken T , RihaniA, Van GoethemA, De PaepeA, SpelemanF, VandesompeleJ. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett.344 (2), 157–165 (2014).
   PubMed Web of Science ®Google Scholar
• Joseph TL , MadhumalarA, BrownCJ, LaneDP, VermaCS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle9 (6), 1167–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Deshaies RJ , JoazeiroCA. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem.78399–434 (2009).
   PubMed Web of Science ®Google Scholar
• Petroski MD , DeshaiesRJ. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol.6 (1), 9–20 (2005).
   PubMed Web of Science ®Google Scholar
• Aghajan M , JonaiN, FlickKet al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol.28 (7), 738–742 (2010).
   PubMed Web of Science ®Google Scholar
• Chen BB , CoonTA, GlasserJRet al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat. Immunol.14 (5), 470–479 (2013).
   PubMed Web of Science ®Google Scholar
• Frescas D , PaganoM. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer8 (6), 438–449 (2008).
   PubMed Web of Science ®Google Scholar
• Bielskiene K , BagdonieneL, MozuraitieneJ, KazbarieneB, JanulionisE. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas)51 (1), 1–9 (2015).
   PubMed Web of Science ®Google Scholar
• Skaar JR , PaganJK, PaganoM. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov.13 (12), 889–903 (2014).
   PubMed Web of Science ®Google Scholar
• Ub Pharma overview. http://www.onenucleus.com/media/Events/ONC%20Seminar/Oncology%20seminar%20UB%20Pharma%20111011.pdf
   Google Scholar
• Nakayama K , NagahamaH, MinamishimaYAet al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell6 (5), 661–672 (2004).
   PubMed Web of Science ®Google Scholar
• Chan CH , LiCF, YangWLet al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell149 (5), 1098–1111 (2012).
   PubMed Web of Science ®Google Scholar
• Hershko DD . Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer112 (7), 1415–1424 (2008).
   PubMed Web of Science ®Google Scholar
• Lin HK , WangG, ChenZet al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol.11 (4), 420–432 (2009).
   PubMed Web of Science ®Google Scholar
• Chan CH , LeeSW, LiCFet al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat. Cell Biol.12 (5), 457–467 (2010).
   PubMed Web of Science ®Google Scholar
• Lee SW , LiCF, JinGet al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol. Cell57 (6), 1022–1033 (2015).
   PubMed Web of Science ®Google Scholar
• Zheng N , SchulmanBA, SongLet al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature416 (6882), 703–709 (2002).
   PubMed Web of Science ®Google Scholar
• Hao B , ZhengN, SchulmanBAet al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell20 (1), 9–19 (2005).
   PubMed Web of Science ®Google Scholar
• Sakai T , SakaueH, NakamuraTet al. Skp2 controls adipocyte proliferation during the development of obesity. J. Biol. Chem.282 (3), 2038–2046 (2007).
   PubMed Web of Science ®Google Scholar
• Chan CH , MorrowJK, ZhangS, LinHK. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle13 (5), 679–680 (2014).
   PubMed Web of Science ®Google Scholar
• Ganoth D , BornsteinG, KoTKet al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol.3 (3), 321–324 (2001).
   PubMed Web of Science ®Google Scholar
• Montagnoli A , FioreF, EytanEet al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev.13 (9), 1181–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Tsvetkov LM , YehKH, LeeSJ, SunH, ZhangH. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol.9 (12), 661–664 (1999).
   PubMed Web of Science ®Google Scholar
• Komander D , ClagueMJ, UrbeS. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol.10 (8), 550–563 (2009).
   PubMed Web of Science ®Google Scholar
• Yang Y , KitagakiJ, WangH, HouDX, PerantoniAO. Targeting the ubiquitin–proteasome system for cancer therapy. Cancer Sci.100 (1), 24–28 (2009).
   PubMed Web of Science ®Google Scholar
• Daviet L , CollandF. Targeting ubiquitin specific proteases for drug discovery. Biochimie90 (2), 270–283 (2008).
   PubMed Web of Science ®Google Scholar
• D’arcy P , WangX, LinderS. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol. Ther.147C, 32–54 (2015).
   Google Scholar
• Shinji S , NaitoZ, IshiwataSet al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol. Rep.15 (3), 539–543 (2006).
   PubMed Web of Science ®Google Scholar
• Wu N , LiuC, BaiC, HanYP, ChoWC, LiQ. Over-Expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of beta-catenin. Int. J. Mol. Sci.14 (6), 10749–10760 (2013).
   PubMed Web of Science ®Google Scholar
• Peterson LF , SunH, LiuYet al. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood125 (23), 3588–3597 (2015).
   PubMed Web of Science ®Google Scholar
• Bartholomeusz GA , TalpazM, KapuriaVet al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood109 (8), 3470–3478 (2007).
   PubMed Web of Science ®Google Scholar
• Bartholomeusz G , TalpazM, BornmannW, KongLY, DonatoNJ. Degrasyn activates proteasomal-dependent degradation of c-Myc. Cancer Res.67 (8), 3912–3918 (2007).
   PubMed Web of Science ®Google Scholar
• Seiberlich V , BorchertJ, ZhukarevaV, Richter-LandsbergC. Inhibition of protein deubiquitination by PR-619 activates the autophagic pathway in OLN-t40 oligodendroglial cells. Cell Biochem. Biophys.67 (1), 149–160 (2013).
   PubMed Web of Science ®Google Scholar
• Seiberlich V , GoldbaumO, ZhukarevaV, Richter-LandsbergC. The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases. Biochim. Biophys. Acta1823 (11), 2057–2068 (2012).
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ , RodonL, Gonzalez-JuncaAet al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat. Med.18 (3), 429–435 (2012).
   PubMed Web of Science ®Google Scholar
• Inui M , ManfrinA, MamidiAet al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat. Cell Biol.13 (11), 1368–1375 (2011).
   PubMed Web of Science ®Google Scholar
• Zou Q , JinJ, HuHet al. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat. Immunol.15 (6), 562–570 (2014).
   PubMed Web of Science ®Google Scholar
• Ernst A , AvvakumovG, TongJet al. A strategy for modulation of enzymes in the ubiquitin system. Science339 (6119), 590–595 (2013).
   PubMed Web of Science ®Google Scholar
• Nalepa G , RolfeM, HarperJW. Drug discovery in the ubiquitin–proteasome system. Nat. Rev. Drug Discov.5 (7), 596–613 (2006).
   PubMed Web of Science ®Google Scholar
• Welcker M , ClurmanBE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer8 (2), 83–93 (2008).
   PubMed Web of Science ®Google Scholar
• Yen HC , ElledgeSJ. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science322 (5903), 923–929 (2008).
   PubMed Web of Science ®Google Scholar
• Yen HC , XuQ, ChouDM, ZhaoZ, ElledgeSJ. Global protein stability profiling in mammalian cells. Science322 (5903), 918–923 (2008).
   PubMed Web of Science ®Google Scholar
• Maspero E , ValentiniE, MariSet al. Structure of a ubiquitin-loaded HECT ligase reveals the molecular basis for catalytic priming. Nat. Struct. Mol. Biol.20 (6), 696–701 (2013).
   PubMed Web of Science ®Google Scholar
• Huang Z , ChoiBK, MujooKet al. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene34 (9), 1105–1115 (2014).
   PubMed Web of Science ®Google Scholar
• Zeng F , XuJ, HarrisRC. Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J.23 (6), 1935–1945 (2009).
   PubMed Web of Science ®Google Scholar
• Persaud A , AlbertsP, HayesMet al. Nedd4–1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J.30 (16), 3259–3273 (2011).
   PubMed Web of Science ®Google Scholar
• Rotin D , KumarS. Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell Biol.10 (6), 398–409 (2009).
   PubMed Web of Science ®Google Scholar
• Maspero E , MariS, ValentiniEet al. Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongation. EMBO Rep.12 (4), 342–349 (2011).
   PubMed Web of Science ®Google Scholar
• Bouyain S , LeahyDJ. Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3. Protein Sci.16 (4), 654–661 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Q , ZhouH, LangdonWY, ZhangJ. E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle13 (12), 1875–1884 (2014).
   PubMed Web of Science ®Google Scholar
• Lutz-Nicoladoni C , WolfD, SopperS. Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front. Oncol.5, 58 (2015).
   PubMed Web of Science ®Google Scholar
• Loeser S , PenningerJM. The ubiquitin E3 ligase Cbl-b in T cells tolerance and tumor immunity. Cell Cycle6 (20), 2478–2485 (2007).
   PubMed Web of Science ®Google Scholar
• Udeshi ND , SvinkinaT, MertinsPet al. Refined preparation and use of anti-diglycine remnant (K-epsilon-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol. Cell. Proteomics12 (3), 825–831 (2013).
   PubMed Web of Science ®Google Scholar
• Nguyen VN , HuangKY, HuangCHet al. Characterization and identification of ubiquitin conjugation sites with E3 ligase recognition specificities. BMC Bioinform.16 (Suppl. 1), S1 (2015).
   PubMedGoogle Scholar